Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 61Daunorubicin 28Specimen Handling 24Etoposide 24Azacitidine 22Decitabine 19Cyclophosphamide 19fludarabine phosphate 18Filgrastim 18Biopsy 18Busulfan 17Idarubicin 16venetoclax 15Peripheral Blood Stem Cell Transplantation 15Mitoxantrone 15Injections 14Vorinostat 12tipifarnib 11Bortezomib 10decitabine and cedazuridine drug combination 9Radiotherapy 9Methotrexate 9alvocidib 8Cyclosporine 8sargramostim 7Melphalan 7Antilymphocyte Serum 7laromustine 6fludarabine 6aldesleukin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Myeloid, Acute × iadademstat × Clear all
NCT06514261 2026-05-13

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

National Cancer Institute (NCI)

Phase 1 Suspended
45 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡